Empowering Refined Antibody Engineering Through De Novo Sequencing Services
With the professional team and advanced platform, Creative Biolabs supports various proteomics services based on our proprietary DASS (Database Assisted Shotgun Sequencing) technology platform, including de novo antibody sequencing services, de novo protein sequencing services, and other MS-based services to satisfy the requests of our worldwide clients.
De novo antibody sequencing refers to the process of determining the amino acid sequence of an antibody without any prior knowledge of its encoding gene or reference sequence. This technique has revolutionized antibody engineering by enabling the discovery and optimization of novel antibodies with desired properties.
Applications in Antibody Engineering
Antibody Discovery
De Novo antibody sequencing allows the identification and characterization of antibodies directly from complex samples, such as patient serum or hybridoma supernatants. This enables the discovery of unique antibodies without the need for prior knowledge of the target antigen, facilitating the development of therapeutic antibodies against novel targets.
Antibody Humanization
One common approach is to humanize antibodies derived from non-human sources, such as mice, by modifying their sequences to make them more compatible with the human immune system. This reduces the risk of immune responses when using therapeutic antibodies in humans.
Antibody Design
De Novo antibody sequencing provides insights into the natural diversity of antibody repertoires, enabling researchers to engineer antibodies with enhanced properties. By analyzing the sequences of naturally occurring antibodies, antibody engineers can identify key residues responsible for specific binding, stability, or effector functions. This information can guide the design of engineered antibodies with improved affinity, stability, or effector functions.
Epitope Mapping
De Novo antibody sequencing can be combined with epitope mapping techniques to determine the precise binding sites of antibodies on their target antigens. This information helps in understanding the interaction between antibodies and antigens, which is crucial for rational antibody design and optimization. It can also aid in identifying conserved epitopes across different strains or variants of a pathogen, facilitating the development of broadly neutralizing antibodies.
Antibody Characterization
De Novo antibody sequencing allows comprehensive characterization of monoclonal antibodies, including the determination of variable region sequences, isotype/subtype determination, and identification of post-translational modifications. This information is vital for assessing antibody quality and biosimilarity, and ensuring consistency during manufacturing processes.
Antibody Conjugation
Refined antibody engineering facilitates the conjugation of antibodies with various payloads, like drugs, radionuclides, or imaging agents. By precisely attaching these payloads to antibodies, targeted drug delivery, radioimmunotherapy, or molecular imaging can be achieved, greatly improving therapeutic outcomes or diagnostic accuracy.
Fig.1 Antibody generation strategies.1
Overall, de novo antibody sequencing empowers antibody engineers with the ability to discover, optimize, and characterize antibodies with desired properties. Creative Biolabs offers this invaluable tool to assist you with antibody engineering and therapeutic antibody development. If you need related services, please contact us for more detailed information.
Reference
- Gallo, Eugenio. "The rise of big data: deep sequencing-driven computational methods are transforming the landscape of synthetic antibody design." Journal of Biomedical Science 31.1 (2024): 29. Distributed under Open Access license CC BY 4.0. The image was modified by revising the title.